샘플 요청 목록

 카트 문의
시장보고서
상품코드
1866638

세계의 중간엽줄기세포 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

Mesenchymal Stem Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 중간엽줄기세포 시장 규모는 2024년에 12억 4,500만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 10.6%로 성장하여 2031년까지 25억 4,200만 달러로 확대될 것으로 예측됩니다.

간엽줄기세포(MSCs)는 골수, 탯줄, 지방조직, 태반 등 다양한 조직에서 유래한 다능성 줄기세포입니다. 강력한 자가 재생능력과 다계통 분화능을 가지고 있으며, 골아세포, 연골세포, 지방세포, 기타 간엽계 유래 세포로 분화할 수 있습니다. MSC는 낮은 면역원성, 면역 조절 작용, 강력한 사이토카인 분비를 특징으로 하며, 재생의료, 면역치료, 항염증 치료에서 중요한 초점이 되고 있습니다. 세포배양 기술, 무혈청 배지, GMP 준수 제조의 발전에 따라 MSC는 전임상 연구에서 임상 적용으로 전환되고 있으며, 정형외과 질환, 심혈관질환, 자가면역질환, 종양학, 조직공학 등 다양한 분야에서 활용되고 있습니다. MSC 산업은 업스트림 공정의 세포 조달, 대규모 배양, 냉동보관, 물류, 치료 제품 개발까지 아우르며 MSC를 세계 세포-유전자 치료제(CGT) 시장의 기반이자 정밀의료의 중요한 추진력으로 자리매김하고 있습니다. 이로 인해 전 세계 투자자와 규제 당국의 주목을 받고 있습니다.

간엽줄기세포(MSC) 산업은 전 세계 세포 및 유전자 치료제 연구개발의 급격한 성장, 고령화에 따른 헬스케어 수요 증가, 재생의료 지원정책에 힘입어 가속 성장 단계에 접어들었습니다. 공개된 연례 보고서에 따르면, 진행 중인 MSC 임상시험의 수는 계속 증가하고 있으며, 2024년에만 미국과 중국에서 300개 이상의 시험이 등록되어 신경질환, 대사질환, 자가면역질환을 대상으로 하고 있습니다. 각국 정부는 혁신에 많은 투자를 하고 있으며, GMP를 준수하는 제조 시설과 품질 표준화를 지원하여 기술적 장벽을 낮추고 있습니다. 다국적 제약사와 지역 CDMO(위탁개발생산기관)와의 빈번한 협력으로 산업 규모의 생산과 빠른 시장 침투가 촉진되고 있습니다. 아시아와 중동의 투자가 증가함에 따라 MSC는 전 세계 정밀의료 및 맞춤의료 개발의 전략적 초점이 될 것으로 예상됩니다.

빠른 성장에도 불구하고 MSC 산업은 복잡한 세포 조달, 대규모 제조의 어려움, 임상 프로토콜의 불일치, 지역마다 다른 규제 요건 등의 문제에 직면해 있습니다. 많은 기업들이 공정 최적화 및 배치 간 일관성에 대한 성숙된 경험이 부족하여 고비용 및 상업화까지의 시간이 길어지고 있습니다. 지적재산권 장벽, 국경을 초월한 임상 인증, 세계 규제의 복잡성은 특히 중소규모의 플레이어에게 진입장벽을 더욱 높이고 있습니다. 자본시장의 변동성, 의료보험의 상환 정책과 같은 시장의 불확실성도 위험요소로 작용합니다. 엄격한 품질 기준, 비용 효율성, 합리적인 가격의 균형을 맞추는 것이 경쟁 구도를 형성하는 데 매우 중요할 것입니다.

수요는 기초연구에서 상업적 임상 적용으로 빠르게 이동하고 있습니다. 면역치료, 조직공학, 맞춤의료의 성장과 함께 심혈관 복구, 연골재생, 자가면역질환 관리, 노화방지, 의료미용 등 MSC의 사용사례가 확대되고 있습니다. mRNA 기술 및 유전자 편집 기술과의 새로운 융합이 진행되면서 고품질 맞춤형 MSC 제품에 대한 엄청난 기회가 창출되고 있습니다. 기업 및 연구기관은 제품의 일관성 향상과 비용 절감을 위해 자동화 및 디지털 프로세스 제어를 가속화하고 있습니다. 고령화 인구의 증가, 만성질환의 확산, 지원적인 정책 프레임워크의 융합과 함께 향후 5년간 MSC는 세계 세포 치료제 시장의 핵심 성장 동력이 될 것입니다.

이 보고서는 세계 중간엽줄기세포 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총매출액, 주요 기업의 시장 점유율과 순위에 초점을 맞추고 지역별, 국가별, 유형별, 용도별 분석을 포함하고 있습니다.

간엽줄기세포 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적, 정성적 분석을 통해 독자들이 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 간엽줄기세포 관련 정보에 입각한 비즈니스 의사결정을 할 수 있도록 도와드립니다.

시장 세분화

기업별

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

유형별 부문

  • 제대 유래 MSC
  • 골수 유래 MSC
  • 태반 유래 MSC
  • 기타

용도별 부문

  • 조사
  • 질환 치료
  • 미용·안티에이징
  • 보존

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트
    • 기타 중동 및 아프리카
KSM 25.11.26

The global market for Mesenchymal Stem Cells was estimated to be worth US$ 1245 million in 2024 and is forecast to a readjusted size of US$ 2542 million by 2031 with a CAGR of 10.6% during the forecast period 2025-2031.

Mesenchymal Stem Cells (MSCs) are multipotent stem cells derived from various tissues such as bone marrow, umbilical cord, adipose tissue, and placenta. They possess strong self-renewal and multilineage differentiation capabilities, enabling them to differentiate into osteoblasts, chondrocytes, adipocytes, and other mesenchymal-origin cells. MSCs are characterized by low immunogenicity, immunomodulatory effects, and robust cytokine secretion, making them a key focus in regenerative medicine, immune therapy, and anti-inflammatory treatment. With advancements in cell culture techniques, serum-free media, and GMP-compliant manufacturing, MSCs are transitioning from preclinical research to clinical applications, finding broad use in orthopedic disorders, cardiovascular diseases, autoimmune conditions, oncology, and tissue engineering. The MSC industry spans upstream cell sourcing, large-scale expansion, cryopreservation, logistics, and therapeutic product development, positioning MSCs as a cornerstone of the global cell and gene therapy (CGT) market and a critical driver of precision medicine, drawing strong attention from investors and regulatory authorities worldwide.

The mesenchymal stem cell (MSC) industry is entering a phase of accelerated growth, driven by the global boom in cell and gene therapy R&D, rising healthcare needs of aging populations, and supportive regenerative medicine policies. According to public annual reports, the number of ongoing MSC clinical trials continues to grow, with over 300 trials registered in the U.S. and China in 2024 alone, covering neurological, metabolic, and autoimmune disorders. Governments are investing heavily in innovation, supporting GMP-compliant manufacturing facilities and quality standardization, reducing technical barriers. Frequent collaborations between multinational pharmaceutical companies and regional CDMOs are facilitating industrial-scale production and rapid market penetration. With increasing investments from Asia and the Middle East, MSCs are poised to become a strategic focus in global precision and personalized medicine development.

Despite rapid growth, the MSC industry faces challenges such as complex cell sourcing, difficulties in large-scale manufacturing, inconsistent clinical protocols, and varying regulatory requirements across regions. Many companies lack mature experience in process optimization and batch consistency, resulting in high costs and extended commercialization timelines. Intellectual property barriers, cross-border clinical certifications, and global regulatory complexities further increase entry thresholds, particularly for small and mid-sized players. Market uncertainties, including fluctuations in capital markets and healthcare reimbursement policies, also pose risks. Balancing strict quality standards, cost efficiency, and accessible pricing will be critical for shaping the competitive landscape.

Demand is rapidly shifting from basic research to commercial clinical applications. The growth of immunotherapy, tissue engineering, and personalized medicine is expanding MSC use cases, including cardiovascular repair, cartilage regeneration, autoimmune disease management, anti-aging therapies, and medical aesthetics. Emerging integration with mRNA technology and gene editing is creating vast opportunities for premium, customized MSC products. Companies and research institutions are accelerating automation and digital process control to enhance product consistency and reduce costs. The convergence of aging demographics, chronic disease prevalence, and supportive policy frameworks positions MSCs as a central growth engine in the global cell therapy market over the next five years.

This report aims to provide a comprehensive presentation of the global market for Mesenchymal Stem Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mesenchymal Stem Cells by region & country, by Type, and by Application.

The Mesenchymal Stem Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesenchymal Stem Cells.

Market Segmentation

By Company

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

Segment by Type

  • Umbilical Cord Derived MSC
  • Bone Marrow Derived MSC
  • Placenta Derived MSC
  • Other

Segment by Application

  • Research
  • Disease Treatment
  • Beauty and Anti-aging
  • Storage

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Mesenchymal Stem Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Mesenchymal Stem Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Mesenchymal Stem Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Mesenchymal Stem Cells Product Introduction
  • 1.2 Global Mesenchymal Stem Cells Market Size Forecast (2020-2031)
  • 1.3 Mesenchymal Stem Cells Market Trends & Drivers
    • 1.3.1 Mesenchymal Stem Cells Industry Trends
    • 1.3.2 Mesenchymal Stem Cells Market Drivers & Opportunity
    • 1.3.3 Mesenchymal Stem Cells Market Challenges
    • 1.3.4 Mesenchymal Stem Cells Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Mesenchymal Stem Cells Players Revenue Ranking (2024)
  • 2.2 Global Mesenchymal Stem Cells Revenue by Company (2020-2025)
  • 2.3 Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Mesenchymal Stem Cells Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • 2.6 Mesenchymal Stem Cells Market Competitive Analysis
    • 2.6.1 Mesenchymal Stem Cells Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Mesenchymal Stem Cells Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Umbilical Cord Derived MSC
    • 3.1.2 Bone Marrow Derived MSC
    • 3.1.3 Placenta Derived MSC
    • 3.1.4 Other
  • 3.2 Global Mesenchymal Stem Cells Sales Value by Type
    • 3.2.1 Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Mesenchymal Stem Cells Sales Value, by Type (2020-2031)
    • 3.2.3 Global Mesenchymal Stem Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Research
    • 4.1.2 Disease Treatment
    • 4.1.3 Beauty and Anti-aging
    • 4.1.4 Storage
  • 4.2 Global Mesenchymal Stem Cells Sales Value by Application
    • 4.2.1 Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Mesenchymal Stem Cells Sales Value, by Application (2020-2031)
    • 4.2.3 Global Mesenchymal Stem Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Mesenchymal Stem Cells Sales Value by Region
    • 5.1.1 Global Mesenchymal Stem Cells Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Mesenchymal Stem Cells Sales Value by Region (2020-2025)
    • 5.1.3 Global Mesenchymal Stem Cells Sales Value by Region (2026-2031)
    • 5.1.4 Global Mesenchymal Stem Cells Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.2.2 North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.3.2 Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.5.2 South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Mesenchymal Stem Cells Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.3.2 United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.4.2 Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.5.2 China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.6.2 Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.7.2 South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.9.2 India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CellResearch
    • 7.1.1 CellResearch Profile
    • 7.1.2 CellResearch Main Business
    • 7.1.3 CellResearch Mesenchymal Stem Cells Products, Services and Solutions
    • 7.1.4 CellResearch Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.1.5 CellResearch Recent Developments
  • 7.2 StemCord
    • 7.2.1 StemCord Profile
    • 7.2.2 StemCord Main Business
    • 7.2.3 StemCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.2.4 StemCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.2.5 StemCord Recent Developments
  • 7.3 Cytopeutics
    • 7.3.1 Cytopeutics Profile
    • 7.3.2 Cytopeutics Main Business
    • 7.3.3 Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
    • 7.3.4 Cytopeutics Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Cytopeutics Recent Developments
  • 7.4 CryoCord
    • 7.4.1 CryoCord Profile
    • 7.4.2 CryoCord Main Business
    • 7.4.3 CryoCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.4.4 CryoCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.4.5 CryoCord Recent Developments
  • 7.5 Cell Malaysia
    • 7.5.1 Cell Malaysia Profile
    • 7.5.2 Cell Malaysia Main Business
    • 7.5.3 Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
    • 7.5.4 Cell Malaysia Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Cell Malaysia Recent Developments
  • 7.6 Bangkok Stem Cell
    • 7.6.1 Bangkok Stem Cell Profile
    • 7.6.2 Bangkok Stem Cell Main Business
    • 7.6.3 Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.6.4 Bangkok Stem Cell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Bangkok Stem Cell Recent Developments
  • 7.7 Vinmec Stem Cell Institute
    • 7.7.1 Vinmec Stem Cell Institute Profile
    • 7.7.2 Vinmec Stem Cell Institute Main Business
    • 7.7.3 Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
    • 7.7.4 Vinmec Stem Cell Institute Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Vinmec Stem Cell Institute Recent Developments
  • 7.8 ProSTEM
    • 7.8.1 ProSTEM Profile
    • 7.8.2 ProSTEM Main Business
    • 7.8.3 ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
    • 7.8.4 ProSTEM Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.8.5 ProSTEM Recent Developments
  • 7.9 Cryoviva
    • 7.9.1 Cryoviva Profile
    • 7.9.2 Cryoviva Main Business
    • 7.9.3 Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
    • 7.9.4 Cryoviva Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Cryoviva Recent Developments
  • 7.10 StemCells21
    • 7.10.1 StemCells21 Profile
    • 7.10.2 StemCells21 Main Business
    • 7.10.3 StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
    • 7.10.4 StemCells21 Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.10.5 StemCells21 Recent Developments
  • 7.11 Lonza
    • 7.11.1 Lonza Profile
    • 7.11.2 Lonza Main Business
    • 7.11.3 Lonza Mesenchymal Stem Cells Products, Services and Solutions
    • 7.11.4 Lonza Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Lonza Recent Developments
  • 7.12 Thermo Fisher Scientific
    • 7.12.1 Thermo Fisher Scientific Profile
    • 7.12.2 Thermo Fisher Scientific Main Business
    • 7.12.3 Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
    • 7.12.4 Thermo Fisher Scientific Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Thermo Fisher Scientific Recent Developments
  • 7.13 PromoCell
    • 7.13.1 PromoCell Profile
    • 7.13.2 PromoCell Main Business
    • 7.13.3 PromoCell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.13.4 PromoCell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.13.5 PromoCell Recent Developments
  • 7.14 Stemcell Technologies
    • 7.14.1 Stemcell Technologies Profile
    • 7.14.2 Stemcell Technologies Main Business
    • 7.14.3 Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
    • 7.14.4 Stemcell Technologies Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Stemcell Technologies Recent Developments
  • 7.15 Bio-Techne
    • 7.15.1 Bio-Techne Profile
    • 7.15.2 Bio-Techne Main Business
    • 7.15.3 Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
    • 7.15.4 Bio-Techne Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Bio-Techne Recent Developments
  • 7.16 ATCC
    • 7.16.1 ATCC Profile
    • 7.16.2 ATCC Main Business
    • 7.16.3 ATCC Mesenchymal Stem Cells Products, Services and Solutions
    • 7.16.4 ATCC Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.16.5 ATCC Recent Developments
  • 7.17 Merck
    • 7.17.1 Merck Profile
    • 7.17.2 Merck Main Business
    • 7.17.3 Merck Mesenchymal Stem Cells Products, Services and Solutions
    • 7.17.4 Merck Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Merck Recent Developments

8 Industry Chain Analysis

  • 8.1 Mesenchymal Stem Cells Industrial Chain
  • 8.2 Mesenchymal Stem Cells Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Mesenchymal Stem Cells Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Mesenchymal Stem Cells Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제